We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.69B
AUM Growth
+$682M
Cap. Flow
-$395M
Cap. Flow %
-5.9%
Top 10 Hldgs %
54.02%
Holding
678
New
246
Increased
85
Reduced
72
Closed
235

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$85.8M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$59.6M
3
BCAX
Bicara Therapeutics
BCAX
+$45.8M
4
MRUS
Merus
MRUS
+$34.4M
5
VTRS icon
Viatris
VTRS
+$30M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$102M
2
SGRY icon
Surgery Partners
SGRY
+$86.4M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$53.7M
4
IART icon
Integra LifeSciences
IART
+$42.8M
5
BNTX icon
BioNTech
BNTX
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.45%
2 Industrials 0.73%
3 Technology 0.55%
4 Financials 0.45%
5 Consumer Discretionary 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PNC icon
376
PNC Financial Services
PNC
$99.1B
$288K ﹤0.01%
1,559
-3,731
-71% -$654K
CEVA icon
377
CEVA Inc
CEVA
$831M
$288K ﹤0.01%
+11,915
New +$259K
UCB
378
United Community Banks
UCB
$4.26B
$285K ﹤0.01%
+9,800
New +$281K
IMO icon
379
Imperial Oil
IMO
$62.3B
$284K ﹤0.01%
+4,027
New +$285K
WBD icon
380
Warner Bros
WBD
$64.3B
$281K ﹤0.01%
34,113
-75,712
-69% -$592K
WWD icon
381
Woodward
WWD
$23B
$280K ﹤0.01%
1,632
-16
-1% -$2.66K
UWMC icon
382
UWM Holdings
UWMC
$672M
$277K ﹤0.01%
+32,544
New +$274K
ENSG icon
383
The Ensign Group
ENSG
$10.6B
$277K ﹤0.01%
+1,927
New +$275K
RTX icon
384
RTX Corp
RTX
$290B
$277K ﹤0.01%
+2,285
New +$261K
QS icon
385
QuantumScape Corp
QS
$3.05B
$275K ﹤0.01%
+47,893
New +$295K
SSNC icon
386
SS&C Technologies
SSNC
$18.9B
$275K ﹤0.01%
+3,704
New +$263K
EFOR
387
Everforth Inc
EFOR
$960M
$271K ﹤0.01%
+2,911
New +$270K
RYAN icon
388
Ryan Specialty Holdings
RYAN
$6.02B
$271K ﹤0.01%
+4,082
New +$255K
TGTX icon
389
TG Therapeutics
TGTX
$8.19B
$268K ﹤0.01%
+11,478
New +$251K
MMSI icon
390
Merit Medical Systems
MMSI
$4.82B
$267K ﹤0.01%
+2,697
New +$247K
TRGP icon
391
Targa Resources
TRGP
$56.8B
$263K ﹤0.01%
1,776
-3,618
-67% -$509K
VVX icon
392
V2X
VVX
$2.7B
$259K ﹤0.01%
+4,639
New +$236K
CACI icon
393
CACI
CACI
$10.8B
$258K ﹤0.01%
512
-1,016
-66% -$470K
XPO icon
394
XPO
XPO
$23.4B
$257K ﹤0.01%
+2,386
New +$267K
GKOS icon
395
Glaukos
GKOS
$9.49B
$252K ﹤0.01%
+1,938
New +$241K
CRMT icon
396
America's Car Mart
CRMT
$25.9M
$251K ﹤0.01%
5,979
-16,288
-73% -$945K
MTD icon
397
Mettler-Toledo International
MTD
$28.1B
$247K ﹤0.01%
+165
New +$232K
LXRX icon
398
Lexicon Pharmaceuticals
LXRX
$1.03B
$246K ﹤0.01%
+156,860
New +$279K
DVAX
399
DELISTED
Dynavax Technologies
DVAX
$240K ﹤0.01%
+21,560
New +$238K
XPOF icon
400
Xponential Fitness
XPOF
$286M
$239K ﹤0.01%
+19,255
New +$283K
14 15
16
17 18

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2024 Portfolio in Review

As of Q3 2024, Deerfield Management held 678 positions worth $6.69B, up 11% from $6.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $395M in Q3 2024, closing 235 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Industrials and Technology.

Against the trend, Deerfield Management opened a new position in Indivior Pharmaceuticals worth $49.7M.

  • Deerfield Management's largest Q3 2024 buy was Indivior Pharmaceuticals: 5,092,642 shares worth $49.7M.
  • Deerfield Management added most to Neurocrine Biosciences in Q3 2024, an estimated $85.8M increase.
  • Deerfield Management's biggest Q3 2024 reduction was Surgery Partners, cutting an estimated $86.4M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2024, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 54% of its $6.69B portfolio in Q3 2024.
  • Deerfield Management opened 246 new positions and closed 235 in Q3 2024.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $6.69B.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.